Radiotherapy for Brain Metastases from Renal Cell Cancer: Should Whole‑Brain Radiotherapy Be Added to Stereotactic Radiosurgery?

On multivariate analyses, improved OS was associated with the absence of extracerebral metastases (p < 0.001) and RPA class (p = 0.04), and IC with treatment (p = 0.019). SRS provided a 1‑year, 2‑year, and 3‑year LC probability of 81%, 78%, and 55%, respectively. No association between LC and any of the potential prognostic factors was observed. The results of the subgroup analyses, regarding treatment modality, were similar to the entire cohort, particularly for RPA class I patients. Conclusion: Addition of WBRT to SRS offers better IC and should be considered for RCC patients with one to three brain me‑ tastases, especially in RPA class I group. SRS offers excellent LC rates, while WBRT should be reserved for patients with multiple metastases and poor prognosis.